Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Dauphin

Interventional Cardiology Hattiesburg, MS Medical Doctor

NPI 1962866004 CMS profile 2779854

415 S 28Th Ave, Hattiesburg, MS 39401

Open in the dashboard

General payments

$9,120

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Dauphin of Hattiesburg, MS is reported in the CMS Open Payments database as having received $9,120 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $488 17
2024 General $3,235 47
2023 General $2,007 35
2022 General $657 25
2021 General $1,387 34
2020 General $607 19
2019 General $738 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Dauphin
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Patrick Dauphin were reported at $488. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Patrick Dauphin Interventional Cardiology median Middle half National median
2019 $738 $1,097 $329–$3,048 $163
2020 $607 $473 $161–$1,480 $114
2021 $1,387 $677 $233–$1,827 $132
2022 $657 $978 $333–$2,724 $149
2023 $2,007 $1,136 $382–$2,986 $160
2024 $3,235 $1,181 $395–$3,326 $164
2025 $488 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,362 13 payments
  2. Abiomed $1,108 16 payments
  3. AstraZeneca Pharmaceuticals LP $864 14 payments
  4. Boston Scientific Corporation $662 9 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $645 14 payments
  6. Penumbra, Inc. $575 5 payments
  7. Inari Medical, Inc. $479 10 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $428 6 payments
  9. Pfizer Inc. $424 28 payments
  10. Philips Electronics North America Corporation $311 4 payments
  11. Other $2,263 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,103 200 payments
  2. Travel and Lodging $1,017 4 payments
Products named General payments · program years 2019–2025
  1. TurboHawk $1,287 9 payments
  2. Impella $865 12 payments
  3. JARDIANCE $604 12 payments
  4. FLOWTRIEVER CATHETER, S $601 11 payments
  5. Indigo System $481 4 payments
  6. FARXIGA $440 4 payments
  7. LifeVest $428 6 payments
  8. CT THROMBECTOMY SYSTEM KIT $358 9 payments
  9. BRILINTA $337 9 payments
  10. ELIQUIS $283 18 payments
  11. Other $3,424 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

245

Median for Cardiology: 2,533

Drug cost

$1,907

Median for Cardiology: $485,213

Branded share of claims

38.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 70 $750
Atorvastatin Calcium Generic 33 $312
Metoprolol Succinate Generic 24 $296
Rosuvastatin Calcium Generic 45 $277
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 25 $153
Carvedilol Generic 13 $58
Pantoprazole Sodium Generic 19 $32
Amlodipine Besylate Generic 16 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$72,896

Of which drugs: $178

Medicare patients

208

Average age 74

Services billed

660

107 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 50%
Diabetes 41%
Depression 34%
Heart failure 33%
Atrial fibrillation 32%
Chronic kidney disease 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 19 76 $178

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $88
$88 — —
ELIQUIS
  • PFIZER INC. $38
  • E.R. Squibb & Sons, L.L.C. $15
$53 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $41
$41 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $36
$36 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record